TCTMD

Drug-Coated Balloons Beat Angioplasty for SFA In-Stent Restenosis, but Long-Term Solutions Needed

Patients with symptomatic in-stent restenosis (ISR) of the superficial femoral artery (SFA) or proximal popliteal artery have better primary patency at 1 year if they received a drug-coated balloon ...
Healio

Drug-eluting balloons show promise in SFA in-stent restenosis

Please provide your email address to receive an email when new articles are posted on . A primary patency rate of more than 70% was reported in a cohort of patients who received drug-eluting balloons ...
TCTMD

Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired

Hollywood, FL—Angioplasty with a drug-coated balloon for the treatment of in-stent restenosis of the superficial femoral artery (SFA) achieves significantly better patency at 12 months compared with ...
Fierce Healthcare

Medtronic Advances Research on Peripheral Devices, Highlights Upcoming Presentations

MINNEAPOLIS--(BUSINESS WIRE)-- A global leader in advancing the treatment of cardiovascular disease through innovative medical technology, Medtronic, Inc. (NYSE: MDT) today announced recent milestones ...
Business Wire

Cook Medical Receives FDA Approval for First 5 mm Diameter SFA Drug-Eluting Stent

BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical announced that a new 5 mm diameter version of Zilver ® PTX ® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths ...
News Medical

Medtronic to present clinical trial data of IN.PACT drug-eluting balloon technology at EuroPCR meeting

A global leader in advancing the treatment of cardiovascular disease through innovative medical technology, Medtronic, Inc. (NYSE: MDT) today announced recent milestones in its clinical program for ...
Business Wire

PQ Bypass Announces Unconditional IDE Approval From U.S. FDA to Start TORUS SFA Stent Graft Pivotal Study (TORUS-2)

MILPITAS, Calif.--(BUSINESS WIRE)--PQ Bypass, Inc., a clinical-stage medical device company, today announced it has received full approval of its investigational device exemption (IDE) trial of the ...
Medscape

Durable Patency With Superficial Femoral Artery Stenting

November 21, 2011 (New York, New York) — Three-year follow-up of the RESILIENT trial has shown that the LifeStent vascular stent (Bard Peripheral Vascular) leads to durable benefits and clinical ...
EurekAlert!

Results of the COBRA trial reported at TCT 2011

SAN FRANCISCO, CA – NOVEMBER 11, 2011 – A clinical trial of patients with diabetes has demonstrated that cryoplasty post-dilitation compared to conventional balloon angioplasty in the superficial ...
Healio

Stent thrombosis somewhat common after SFA revascularization

Please provide your email address to receive an email when new articles are posted on . Among patients who had endovascular revascularization of the superficial femoral artery, stent thrombosis ...
AOL

Cordis Acquires Flexible Stenting Solutions, Inc.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cordis Corporation, a worldwide leader in the development of interventional vascular technology, today announced it has completed the acquisition of Flexible ...